Stem Cell Therapeutics Corp. Announces the Extension of the Expiring Date for $7.7 Million Dollars of Outstanding Warrants

CALGARY, ALBERTA--(Marketwire - April 16, 2010) - Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE:SSS) announces the receipt of approval from the TSX Venture Exchange ("TSX-V") to extend the expiry date of the $0.50 warrants issued in conjunction with a financing dated November 9, 2007 from May 9, 2010 to June 30, 2010.

Dr. Alan Moore, President and CEO of SCT commented as follows:

"With our modified REGENISIS-LED enrolment completed and results expected in Q2, this extension will allow these warrant holders to make a more informed decision on exercising their warrants. If all remaining warrant holders from our November 2007 financing choose to exercise their warrants, this would provide $7.7 million to SCT without any financing fees or further issue of warrants."

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a Canadian public biotechnology company (TSX-V: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair neurological function lost due to disease or injury. SCT's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.